

Table S1. Adverse events (AEs) in the low and normal PMI groups

	Grade 3 or worse			Any grade		
	normal PMI (n = 68)	Low PMI (n = 64)	P value	normal PMI	Low PMI	P value
Hypertension	2 (2.9%)	3 (4.7%)	0.604	24 (35.3%)	25 (39.1%)	0.648
Diarrhea	2 (2.9%)	1 (1.6%)	0.604	14 (20.6%)	13 (20.3%)	0.976
Anorexia	1 (1.5%)	4 (6.3%)	0.153	25 (36.8%)	24 (37.5%)	0.926
Fatigue	1 (1.5%)	4 (6.3%)	0.153	29 (42.6%)	19 (29.7%)	0.123
Hoarseness	0 (0%)	0 (0%)		10 (14.7%)	11 (17.2%)	0.696
Hypothyroidism	0 (0%)	0 (0%)		21 (30.9%)	20 (31.3%)	0.96
Body weight loss	0 (0%)	0 (0%)		10 (14.7%)	7 (10.9%)	0.524
Hand foot syndrome	2 (2.9%)	3 (4.7%)	0.569	27 (39.7%)	21 (32.8%)	0.415
Proteinuria	4 (5.9%)	7 (10.9%)	0.296	18 (26.5%)	15 (23.4%)	0.694
Liver damage	1 (1.5%)	1 (1.6%)	0.973	7 (10.3%)	6 (9.4%)	0.866
Hepatic encephalopathy	3 (4.4%)	1 (1.6%)	0.774	4 (5.9%)	3 (4.7%)	0.753

AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

PMI: psoas muscle index, Low PMI group: PMI <6.0 cm<sup>2</sup>/m<sup>2</sup> for men and <3.4 cm<sup>2</sup>/m<sup>2</sup> for women, normal PMI group: PMI ≥6.0 cm<sup>2</sup>/m<sup>2</sup> for men and ≥3.4 cm<sup>2</sup>/m<sup>2</sup> for women.

Table S2. Adverse events (AEs) in the severe and mild atrophy groups

	Grade 3 or worse			Any grade		
	Mild atrophy (n = 67)	Severe atrophy (n = 65)	P value	Mild atrophy	Severe atrophy	P value
Hypertension	<b>5 (7.5%)</b>	<b>0 (0%)</b>	<b>0.024</b>	21 (38.8%)	23 (35.4%)	0.589
Diarrhea	3 (4.5%)	0 (0%)	0.082	16 (23.9%)	11 (16.9%)	0.282
Anorexia	2 (3.0%)	3 (4.6%)	0.655	24 (35.8%)	25 (38.5%)	0.858
Fatigue	1 (1.5%)	4 (6.2%)	0.175	23 (34.3%)	25 (38.5%)	0.718
Hoarseness	0 (0%)	0 (0%)		11 (16.4%)	10 (15.4%)	0.815
Hypothyroidism	0 (0%)	0 (0%)		18 (26.9%)	23 (35.4%)	0.347
Body weight loss	0 (0%)	0 (0%)		10 (14.9%)	7 (10.8%)	0.439
Hand foot syndrome	2 (3.0%)	3 (4.6%)	0.655	23 (34.3%)	25 (38.5%)	0.718
Proteinuria	8 (11.8%)	3 (4.6%)	0.117	11 (28.4%)	14 (21.5%)	0.316
Liver damage	1 (1.5%)	1 (1.5%)	1	6 (9.0%)	7 (10.8%)	0.774
Hepatic encephalopathy	2 (3.0%)	2 (3.1%)	0.602	3 (4.5%)	4 (6.2%)	0.69

AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

PMI: psoas muscle index, Severe atrophy group:  $\Delta$ PMI/m rate >1%, Mild atrophy group:  $\Delta$ PMI/m rate <1%.